Phase 3 Heart Disease Trial, Recruiting NCT07381803 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Heart Disease
Back to Heart Disease

Phase 3 Heart Disease Trial, Recruiting

NCT07381803
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older.
  • People who are able to verbally show they understand the risks, benefits, and treatment options involved, and who (or whose legal representative) are willing to sign a written consent form before the trial begins.
  • People who have had an acute heart attack of a specific type (called STEMI) within the past 7 days, confirmed by a combination of chest pain symptoms lasting more than 10–20 minutes, a blood test showing elevated heart damage markers, and specific changes seen on a heart tracing (ECG).
  • People whose heart ultrasound (echocardiogram) shows that part of the heart wall is not moving properly.

Who may not be able to join:

  • People who need to take fexofenadine hydrochloride or similar allergy-blocking medicines (called H1 receptor inhibitors) on an ongoing, long-term basis.
  • People who have previously had open-heart bypass surgery (CABG).
  • People with a history of severely reduced kidney function (eGFR below 30 ml/min).
  • People with a history of severe liver problems.
  • People with a history of a serious active infection, a blockage in the liver or bile ducts, or a cancer diagnosis.
  • People whose life expectancy is estimated to be less than 2 years due to a non-heart-related illness.
  • People who are currently taking medicines that suppress the immune system.
  • People who are pregnant, possibly pregnant, or currently breastfeeding.
  • People for whom the study drug or any required tests or procedures are not medically suitable (confirm with trial site).
  • People who are unable or unwilling to provide written consent to participate.
  • People who, at the time of enrolment, have certain serious heart complications, such as a hole between heart chambers, severe leakage of a heart valve, shock that is not responding to medicines, acute heart failure or fluid on the lungs, or dangerous irregular heart rhythms that cannot be controlled with medication.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8615088555539

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
27 January 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Major adverse cardiovascular and cerebrovascular events (MACCE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov